Bank Of America Corp Beyond Spring Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Beyond Spring Inc. stock. As of the latest transaction made, Bank Of America Corp holds 8,000 shares of BYSI stock, worth $12,960. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,000

Previous 8,000 -0.0%

Holding current value

$12,960

Previous $19,000 5.26%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.76 - $3.6 $8,789 - $17,978	-4,994 Reduced 38.43%	8,000 $19,000
Q1 2024 May 15, 2024	BUY	$0.85 - $3.63 $4,017 - $17,159	4,727 Added 57.18%	12,994 $46,000
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.12 $89 - $148	133 Added 1.64%	8,267 $7,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.39 $23,350 - $36,468	-26,236 Reduced 76.33%	8,134 $9,000
Q1 2023 May 12, 2023	BUY	$1.06 - $3.05 $7,432 - $21,386	7,012 Added 25.63%	34,370 $38,000
Q4 2022 Feb 10, 2023	SELL	$0.56 - $2.61 $28,127 - $131,095	-50,228 Reduced 64.74%	27,358 $51,000
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $13,873 - $25,888	-14,303 Reduced 15.57%	77,586 $77,000
Q2 2022 Aug 12, 2022	SELL	$1.13 - $2.66 $44,644 - $105,091	-39,508 Reduced 30.07%	91,889 $132,000
Q1 2022 May 16, 2022	BUY	$1.68 - $5.01 $68,604 - $204,588	40,836 Added 45.09%	131,397 $289,000
Q4 2021 Feb 08, 2022	BUY	$4.02 - $16.84 $145,061 - $607,671	36,085 Added 66.24%	90,561 $411,000
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $137,270 - $464,139	14,824 Added 37.39%	54,476 $859,000
Q2 2021 Sep 13, 2021	BUY	$9.37 - $12.12 $371,539 - $480,582	39,652 New	39,652 $414,000

Others Institutions Holding BYSI

# of Institutions

Shares Held

5.55M

Call Options Held

26K

Put Options Held

2.4K

View Full List

About BeyondSpring Inc.

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $63.1M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

More about BYSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Beyond Spring Inc. Transaction History